Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eye Tracking as a Predictor of Methylphenidate Response in ASD with ADHD
NCT02874690Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Feb 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Change in Eye-Tracking: Microsaccades and pupil size at 90 minutes. Started Feb 2016; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02874690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02874690.